Alzheimer's Disease Drug Development: Another Lost Year
Seeking Alpha,
Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the…
Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the…
Summary Blarcamesine, Aricept, and most probably simufilam are sigma-1 receptor agonists.
Summary Many treatments for Alzheimer's disease limit the formation of peroxynitrite, which can for a while slow down the…
Follow Summary Aricept, blarcamesine, simufilam, and panax ginseng by acting as acetylcholinesterase inhibitors and as indirect…